Previous close | 0.0972 |
Open | 0.0986 |
Bid | 0.0000 x 0 |
Ask | 0.0956 x 0 |
Day's range | 0.0920 - 0.0986 |
52-week range | 0.0362 - 0.1950 |
Volume | |
Avg. volume | 607,624 |
Market cap | 12.155M |
Beta (5Y monthly) | 1.68 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery – Biology, will also be attending this event. In his presentation, Mr Dyer will provide a corporate update and discuss recent development
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at
Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024. In his presentation, Dr Lütjens will provide a corporate update and discuss recent advances from Addex’s CNS pipeline. Present